Evidence map›Paper›PMID 42071032›Full record

ArticleClinical and experimental medicine2026

Dynamic changes in gut microbiota and discovery of prognostic biomarkers in locally advanced pancreatic cancer during chemoradiotherapy.

Haohua Wang, Fuhao Wang, Qi Guo, Benkui Zou, Peihang Li, Xiaoqing Xu, Junyi He, Shumei Jiang, Jinbo Yue

Abstract read
In one paragraph

Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haohua Wang *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Fuhao Wang *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Qi Guo *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Benkui ZouDepartment of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Peihang LiDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Xiaoqing XuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Junyi HeKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Shumei JiangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China. shumeij@163.com.
Jinbo YueDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China. jbyue@sdfmu.edu.cn.

Funding

Collaborative Academic Innovation Project of Shandong Cancer Hospital ZF004National Natural Science Foundation of China 82272753
6 · The paper itself

Abstract

Pancreatic cancer has an exceptionally poor prognosis, with the majority of cases diagnosed at an advanced stage. Concurrent chemoradiotherapy (CCRT) remains the standard of care for locally advanced pancreatic cancer (LAPC); however, its therapeutic efficacy is limited. Emerging evidence suggests that the gut microbiota is an important modulator of cancer progression and treatment response. Nevertheless, the dynamic changes in the gut microbial ecosystem in LAPC patients undergoing CCRT remain poorly understood. This study aimed to characterize longitudinal alterations in the gut microbiota during CCRT, identify candidate microbiome-based prognostic markers, and explore their potential associations with host responses. This longitudinal study included 16 patients with LAPC. Fecal and peripheral blood samples were collected at three predefined time points: before CCRT initiation, during CCRT, and after CCRT completion. Gut microbiota composition and community structure were analyzed using 16 S rRNA sequencing targeting the V3–V4 region. Bioinformatic analyses were performed to assess taxonomic distribution, alpha and beta diversity, and microbial co-occurrence patterns. The prognostic relevance of microbial features was further evaluated using machine learning models integrating clinical parameters to predict overall survival. CCRT was associated with dynamic changes in specific microbial taxa across multiple taxonomic levels, with marked inter-individual heterogeneity in microbiota responses. In addition, microbial co-occurrence network complexity was reduced during treatment. Certain microbial taxa during CCRT showed associations with tumor-related serum biomarkers. Using integrated machine learning models, we identified candidate microbiota-based prognostic markers. In particular, Bifidobacterium and Bacteroides were associated with survival prediction, achieving areas under the receiver operating characteristic curve (AUC) of 0.833 and 0.722, respectively. CCRT is associated with longitudinal alterations in the gut microbiome of patients with LAPC, involving both compositional and structural changes. These findings suggest that microbiome dynamics may have potential value as exploratory prognostic indicators. However, given the limited sample size and observational design, further validation in larger cohorts and mechanistic studies are required before clinical application.

Indexed as

Biomarkers, TumorChemoradiotherapyGastrointestinal MicrobiomePancreatic NeoplasmsAgedFecesFemaleHumansLongitudinal StudiesMaleMiddle AgedPrognosisRNA, Ribosomal, 16SBiomarkers, TumorRNA, Ribosomal, 16SBioinformatics analysisConcurrent chemoradiotherapyGut microbiotaLocally advanced pancreatic cancerPrognostic biomarkers

Identifiers

PMID42071032
PMCPMC13136225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.